Methyl malonyl chloride | CAS:37517-81-0

We serve Methyl malonyl chloride CAS:37517-81-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Methyl malonyl chloride

Chemical Name:Methyl malonyl chloride
CAS.NO:37517-81-0
Synonyms:Methyl malonyl chloride
Propanoic acid, 3-chloro-3-oxo-, methyl ester
METHYL CHLOROFORMYLACETATE
Methyl 3-Chloro-3-Oxopropanoate
Mehtyl Malonyl Chloride
Molecular Formula:C4H5ClO3
Molecular Weight:136.53400
 
Physical and Chemical Properties:
Density:1.278
Boiling point:57-59ºC
Flash point:176°F
Index of Refraction:1.432
 
Specification:
Appearance:Light yellow transparent liquid
Assay:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like Methyl malonyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Mehtyl Malonyl Chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl 3-Chloro-3-Oxopropanoate Use and application,Methyl 3-Chloro-3-Oxopropanoate technical grade,usp/ep/jp grade.


Related News: Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity.4-Piperidin-4-ylmorpholine manufacturer As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.(3S)-3-[4-[(5-bromo-2-chlorophenyl)methyl]phenoxy]oxolane supplier As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.2,6-Dimethylphenylhydrazine hydrochloride vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.